Piśmiennictwo:

1. World Health Organization. Leishmaniasis disease burden. www.who.int/leishmaniasis/en

2. Foreign travel associated illness in England, Wales and Northern Ireland, 2007 report. Arthropod borne diseases: 57-59. www.hpa.org.uk

3. Chappuis F, Rijal S, Soto A, et al. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstik for visceral leishmaniasis. BMJ 2006;333:723-6.

4. Lockwood DN, Sundar S. Serological tests for visceral leishmaniasis. BMJ 2006;333:711-2.

5. Davidson RN, di Martino L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B. Clin Infect Dis 1996;22:938-43.

6. Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010;362:504-12.

7. Seaman J, Mercer AJ, Sondorp HE, et al. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 1996;124:664-72.

8. Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000;31:1104-7.

9. Moore EM, Lockwood DN. Treatment of visceral leishmaniasis. J Glob Infect Dis 2010;2:151-8.

10. Pintado V, Martin-Rabadan P, Rivera ML, et al. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 2001;80:54-73.

11. Morizot G, Delgiudice P, Caumes E, et al. Healing of old world cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg 2007;76:48-52.

12. Marsden PD. Mucosal leishmaniasis (‘espundia’ Escomel 1911). Trans R Soc Trop Med Hyg 1986;80:859-76.

13. Lawn SD, Armstrong M, Chilton D, et al. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg 2006;100:264-9.

14. Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002;346:891-5.

15. Soto J, Arana BA, Toledo J et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004;38:1266-72.

16. Brown M, Noursadeghi M, Boyle J, et al. Successful liposomal amphotericin B treatment of Leishmaniabraziliensis cutaneous leishmaniasis. Br J Dermatol 2005;153:203-5.

17. Reithinger R, Dujardin JC, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis 2007;7:581-96.

18. Herwaldt B. Leishmaniasis. Lancet 1999;354:1191-9.

19. Bailey MS, Green AD, Ellis CJ, et al. Clinical guidelines for the management of cutaneous leishmaniasis in British military personnel. J R Army Med Corps 2005;151:73-80.